Kanebo
This article was originally published in The Rose Sheet
Executive Summary
Kanebo Cosmetics, Inc. is established by new financial backer, Industrial Revitalization Corporation of Japan, company announces May 7. Firm was spun off from parent Kanebo Ltd. after ICRJ purchased the cosmetic division's debt last month. New company "is aiming to tackle investment more actively and to maintain and strengthen competitiveness as well as pursue the goal of customer satisfaction through new concepts of beauty," according to Kanebo. Kunihiko Yogo, a director with the government agency, is appointed director and representative chairman/CEO under a new structure that emphasizes "a high level of transparency," firm says. Kanebo's management will now be divided among nomination, remuneration and auditing committees. The government bailout occurred after competitor Kao Corp. bowed out of negotiations to acquire Kanebo's cosmetics business earlier this year (1"The Rose Sheet" March 1, 2004, In Brief)...
You may also be interested in...
Kao/Kanebo end talks
Japanese firms have ended discussions on Kao's planned acquisition of Kanebo's cosmetics business, Kao says Feb. 16. Plans fell through after Kanebo expressed decision to withdraw from negotiations, according to Kao. "We consider this news extremely unfortunate given our conviction that the plan for the transfer of business, which was in its final stages, was the most ideal option for Kanebo's employees, customers, partners, shareholders and others," Japanese consumer products marketer states. Negotiations hit a hurdle earlier this year when the two firms postponed finalization of a planned merger of their cosmetics businesses. Later, the companies tentatively agreed Kao would purchase Kanebo's cosmetics business outright instead (1"The Rose Sheet" Feb. 9, 2004, In Brief)...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.